Can Medical Device Testing Reports Be Reused for South Korea Registration?

Yes, in many cases testing reports and other technical evidence already prepared for another market can be reused to support a South Korean medical device registration, but reuse is never automatic. Whether an existing report or technical file is accepted depends on four points that must be confirmed first: the target market, the product risk class, the applicable regulatory pathway (including the relevant MFDS requirements), and the quality of the existing documentation base. Only after these are clear should the manufacturer assess technical documentation, quality system evidence, labelling and instructions for use, local agency arrangements, clinical evidence and post-market maintenance requirements. AIMEILI advises completing a documentation gap assessment before formal submission, so that unclear classification, incomplete documentation or unresolved authorisation arrangements do not extend the project timeline.

Published: 15 July 2026, 16:48 | Updated: 15 July 2026, 16:48

This article addresses the questions that manufacturers need to resolve first in practice when working on medical device international registration, documentation preparation, compliance pathways and post-market maintenance.

Key Summary

For Chinese medical device manufacturers, the more reliable judgement is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects technical documentation, authorised representation, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, correction requests and rework are more likely to arise in relation to model coverage, evidence-chain consistency, label claims and certificate control. AIMEILI recommends addressing this question within a consolidated GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets rather than rebuilding documentation on an ad hoc basis in each country.

This content is compiled from AIMEILI's regulatory practice library, its medical device international registration knowledge base and publicly available regulatory information. Individual projects should always be based on the latest requirements of the target country's regulatory authority and on the manufacturer's own product documentation.

Applicable Scenarios and the Core Question

Companies searching for information on whether testing reports can be reused for South Korean registration are usually not looking for a conceptual explanation. What they need to determine is whether their existing documentation can support a submission in the target market, whether a local agent or authorised representative is required, why timelines become extended, and which issues could affect the launch plan. The question typically involves product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities at the same time.

If a manufacturer plans to enter several GHWP member states, or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process question for one country alone is not sufficient. A more valuable approach is to prepare core technical documentation, quality system evidence, performance verification, clinical evidence, and labelling and instructions for use in a reusable version first, and then localise them in line with each country's regulatory requirements.

How to Determine the Registration Pathway

Manufacturers should first confirm the intended use, mechanism of action, use environment, method and duration of body contact, and whether the device is sterile, active, or contains software or IVD characteristics, and only then determine the risk class and submission pathway. If the pathway is misjudged, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a target-market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left vague in the commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, the technical file, performance verification reports, the risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by testing reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulatory authorities focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating NMPA documentation directly and submitting it without reorganising the evidence according to the target market pathway.
• Listing too many models and specifications while testing reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibilities, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation, leading to correction requests or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that documentation is rebuilt for every country and both cost and timelines are amplified.

Manufacturer Preparation Checklist

Before starting a project, manufacturers should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, testing reports, risk management file, clinical evaluation and English-language instructions for use.
• Confirm the duties, fees, certificate control and exit mechanisms of the local agent or authorised representative.
• Establish a target-country gap assessment table identifying what must be re-tested, translated, notarised or supported by additional declarations.

AIMEILI's Perspective

AIMEILI advises manufacturers not to treat target-market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies entering multiple countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster and more stable than supplementing documentation on an ad hoc basis country by country, and it also supports subsequent changes and renewals more effectively.

From a project management perspective, three items should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. Unless these three items are clear, a project may still go through repeated correction requests, agent communications and post-market maintenance issues, no matter how voluminous the documentation appears.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as it stands. Manufacturers need to adjust the structure, language, labelling, authorisation documents and evidence chain of the documentation according to local regulatory requirements.

When is the best time to start the gap assessment?

It is advisable to start immediately after the target market and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent usually participates in registration communication, changes, renewals and post-market event handling. If responsibilities are unclear, certificate control and subsequent market stability may be affected.

Project Execution Recommendations

When executing this type of registration project, manufacturers should maintain a project register that tracks the product list, models and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible early and helps management assess whether the project will affect the launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established, identifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must in particular be kept at consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Build the documentation gap assessment table.
• Clarify the local agent and certificate control arrangements.
• Track translation, notarisation, testing and correction status.
• Plan post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical documentation are consistent. If the scope covered by the ISO 13485 certificate does not match the products being submitted, or if the manufacturing address, models and specifications, or the version of the instructions for use differ from the testing report, the authority may request supplementary explanations even where a large volume of documentation has been prepared.

Manufacturers should establish an evidence consistency checklist before submission, mapping product name, models and specifications, intended use, applicable standards, testing report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificates item by item. Although this step appears basic, it can significantly reduce the likelihood of correction requests, particularly for projects submitting simultaneously across several GHWP member states or for multiple product families.

Localisation and Agent Responsibilities

Target-market registration projects usually involve arrangements with a local agent, authorised representative, importer or registration holder. Manufacturers need to confirm in advance whether the local partner only submits documentation or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorisation documents cannot simply be translated either. Manufacturers should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into a submission structure acceptable in the target country, rather than drafting a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Manufacturers must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining approval but neglect post-market maintenance, so that once a manufacturing address change, model expansion, instructions for use update or agent replacement occurs, the certificate and commercial sales can become disconnected.

AIMEILI recommends managing this question as part of an annual international registration plan: set target market priorities first, then build a reusable documentation package and a country gap list, and finally schedule submission, correction, post-market maintenance and renewal milestones. The value of this approach lies not only in higher efficiency for an individual country registration; more importantly, it allows manufacturers to build a replicable overseas compliance capability and reduces the cost of rebuilding documentation from scratch every time they enter a new market.

Related Reading

• How should a local agent be selected for Brazilian medical device registration?
• How are authorised representative responsibilities divided for Brazilian medical device registration?
• Why do Brazilian medical device registration timelines become extended?
• What are the common reasons for documentation correction requests in Brazilian medical device registration?
• How is post-market surveillance carried out for Brazilian medical device registration?
• When must a registration change be filed for Brazilian medical device registration?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Sourcing principle: official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials are prioritised; industry media and project experience are used only as supporting judgement. Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.